Adaptive Biotechnologies Corp (NASDAQ:ADPT) price on current trading day, rose 9.33% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.38.
A look at the stock’s price movement, the close in the last trading session was $7.66, moving within a range at $7.3 and $8.61. The beta value (5-Year monthly) was 1.73. Turning to its 52-week performance, $9.01 and $2.28 were the 52-week high and 52-week low respectively. Overall, ADPT moved 11.88% over the past month.
Adaptive Biotechnologies Corp’s market cap currently stands at around $1.25 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-10.
Analysts have a consensus estimate of 42.13M for the company’s revenue for the quarter, with a low and high estimate of 39.8M and 44.81M respectively. The average forecast suggests up to a 0.60% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 212.69M, representing a 18.85% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ADPT is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
11 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 6 analyst(s) rate the stock as a Hold, 4 recommend ADPT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ADPT’s current price about 7.59% and 6.36% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 57.80, while 7-day volatility ratio is 15.45% and 9.60% in the 30-day chart. Further, Adaptive Biotechnologies Corp (ADPT) has a beta value of 1.54, and an average true range (ATR) of 0.78. Analysts have given the company’s stock an average 52-week price target of $14, forecast between a low of $5 and high of $18. Looking at the price targets, the low is 40.33% off current price level while to achieve the yearly target high, price needs to move -114.8%. Nonetheless, investors will most likely welcome a -67.06% jump to $14 which is the analysts’ median price.
If we refocus on Adaptive Biotechnologies Corp (NASDAQ:ADPT), historical trading data shows that trading volumes averaged 2.65 over the past 10 days and 1.89 million over the past 3 months. The company’s latest data on shares outstanding shows there are 147.77 million shares.
The 4.61% of Adaptive Biotechnologies Corp’s shares are in the hands of company insiders while institutional holders own 92.58% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.49 million on 2025-03-14, giving us a short ratio of 4.82. The data shows that as of 2025-03-14 short interest in Adaptive Biotechnologies Corp (ADPT) stood at 818.0001000000001 of shares outstanding, with shares short rising to 8.78 million registered in 2025-02-14. Current price change has pushed the stock 39.78% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ADPT stock continues to rise going into the next quarter.
